Decode Your Biomarkers
Do not read every lab flag as a diagnosis, and do not let one 'optimal range' chart set your treatment plan. First identify whether the number is a reference range, a diagnostic or risk threshold, or a personal treatment target. Then ask whether the result is persistent, whether context could distort it, and what decision would change next.
Name the number
Reference range, diagnostic or risk threshold, and treatment target answer different questions.
Use your risk
LDL-C and ApoB goals get lower as cardiovascular risk rises. There is no single target for every adult.
Confirm before reacting
Check symptoms, medications, illness, and prior results before treating one mild abnormality as a diagnosis.
Start by naming the kind of number
Most lab confusion comes from treating three different numbers as if they mean the same thing. They do not.
A result can be statistically unusual without proving disease. A result can also sit inside the printed range and still be above a risk-based treatment goal. Before I interpret a value, I name the job that number is doing.
Protocol
The three numbers people confuse
Lab reference range
- What it tells you
- The range reported by that laboratory, often based on a comparison population and a specific assay.
- What it does not tell you
- It is not a guarantee of health and not an automatic treatment target.
Diagnostic or risk threshold
- What it tells you
- A cutoff used to classify a condition or a higher-risk state, such as the thresholds for diabetes or elevated Lp(a).
- What it does not tell you
- One result does not always establish a diagnosis; confirmation and clinical context may be required.
Personal treatment target
- What it tells you
- A goal chosen after accounting for baseline risk, known disease, treatment benefit, safety, and preference.
- What it does not tell you
- It is not a universal 'optimal range' that every adult needs to reach.
| Type of number | What it tells you | What it does not tell you |
|---|---|---|
| Lab reference range | The range reported by that laboratory, often based on a comparison population and a specific assay. | It is not a guarantee of health and not an automatic treatment target. |
| Diagnostic or risk threshold | A cutoff used to classify a condition or a higher-risk state, such as the thresholds for diabetes or elevated Lp(a). | One result does not always establish a diagnosis; confirmation and clinical context may be required. |
| Personal treatment target | A goal chosen after accounting for baseline risk, known disease, treatment benefit, safety, and preference. | It is not a universal 'optimal range' that every adult needs to reach. |
The same value can be normal by a lab reference range, meaningful as a risk marker, and still above a treatment target. Those are not contradictions.
Use a testing hierarchy
I start with a compact prevention baseline, then add tests when the result has a job. The practical question is not whether a biomarker is interesting. It is whether a high, low, or unchanged result would alter treatment, monitoring, or urgency.
If your immediate question is what to request at a visit, keep this interpretation guide open and use the separate companion guide, 'What labs should I ask my doctor for?', linked below.
Protocol
What belongs on each rung
Core prevention baseline
- Typical tests
- Standard lipid panel; A1C or fasting glucose; CBC; CMP; creatinine/eGFR; blood pressure, which is not a lab but changes the interpretation.
- Why they are there
- Classify common cardiovascular and metabolic risk and catch basic organ or medication-safety issues.
One-time or selective risk refinement
- Typical tests
- Lp(a) once in adulthood; ApoB when risk may be underestimated by LDL-C; uACR in people at kidney risk; hsCRP when inflammatory cardiovascular risk would change the discussion.
- Why they are there
- Refine a real decision rather than make the panel look comprehensive.
Story-driven testing
- Typical tests
- Ferritin and iron studies, B12, TSH, vitamin D, and other targeted tests when symptoms, diet, prior results, medications, or known disease make the answer actionable.
- Why they are there
- Investigate a plausible problem instead of screening broadly for every possible one.
Follow-up
- Typical tests
- The marker tied to the intervention, plus the safety labs that intervention requires.
- Why they are there
- Show whether the plan worked and whether it is safe on a timeline that matches the biology.
| Rung | Typical tests | Why they are there |
|---|---|---|
| Core prevention baseline | Standard lipid panel; A1C or fasting glucose; CBC; CMP; creatinine/eGFR; blood pressure, which is not a lab but changes the interpretation. | Classify common cardiovascular and metabolic risk and catch basic organ or medication-safety issues. |
| One-time or selective risk refinement | Lp(a) once in adulthood; ApoB when risk may be underestimated by LDL-C; uACR in people at kidney risk; hsCRP when inflammatory cardiovascular risk would change the discussion. | Refine a real decision rather than make the panel look comprehensive. |
| Story-driven testing | Ferritin and iron studies, B12, TSH, vitamin D, and other targeted tests when symptoms, diet, prior results, medications, or known disease make the answer actionable. | Investigate a plausible problem instead of screening broadly for every possible one. |
| Follow-up | The marker tied to the intervention, plus the safety labs that intervention requires. | Show whether the plan worked and whether it is safe on a timeline that matches the biology. |
ApoB is selective and risk-based, not mandatory for every routine panel. Lp(a) is usually a once-or-rarely measurement because genetics drive most of the level.
Skip the 100-marker panel when nobody can say what each result would change.
Do not repeat stable markers monthly just because a portal can graph them.
Do not turn one mild abnormality into a diagnosis before checking whether it persists.
LDL-C and triglycerides: the target follows the risk
LDL-C is the clearest example of why a printed reference range is not enough. The 2026 ACC/AHA dyslipidemia guideline brought back explicit treatment goals, and the goal gets lower as cardiovascular risk rises.
I use the goal only after deciding which risk group fits. I also look at the starting value, the percent reduction, treatment tolerance, and the rest of the risk picture.
Protocol
Lipid numbers at a glance
LDL-C, borderline or intermediate primary prevention
- Useful shorthand
- <100 mg/dL
- How I use it
- A risk-based treatment goal when lipid-lowering therapy is chosen, not a diagnostic normal for everyone.
LDL-C, high risk
- Useful shorthand
- <70 mg/dL
- How I use it
- A lower goal for high-risk prevention and many people with established disease who are not in the very-high-risk tier.
LDL-C, very-high-risk ASCVD
- Useful shorthand
- <55 mg/dL
- How I use it
- A secondary-prevention goal for people at very high risk of another ASCVD event.
Triglycerides
- Useful shorthand
- <150 mg/dL
- How I use it
- The conventional normal threshold. Persistent elevation should trigger a look at alcohol, glycemia, diet, weight change, thyroid status, medications, and genetic risk.
Triglycerides
- Useful shorthand
- <100 mg/dL is often favorable
- How I use it
- A useful metabolic signal, but not a mandatory target for every adult and not a reason to chase medication in isolation.
| Marker and context | Useful shorthand | How I use it |
|---|---|---|
| LDL-C, borderline or intermediate primary prevention | <100 mg/dL | A risk-based treatment goal when lipid-lowering therapy is chosen, not a diagnostic normal for everyone. |
| LDL-C, high risk | <70 mg/dL | A lower goal for high-risk prevention and many people with established disease who are not in the very-high-risk tier. |
| LDL-C, very-high-risk ASCVD | <55 mg/dL | A secondary-prevention goal for people at very high risk of another ASCVD event. |
| Triglycerides | <150 mg/dL | The conventional normal threshold. Persistent elevation should trigger a look at alcohol, glycemia, diet, weight change, thyroid status, medications, and genetic risk. |
| Triglycerides | <100 mg/dL is often favorable | A useful metabolic signal, but not a mandatory target for every adult and not a reason to chase medication in isolation. |
These are decision thresholds and goals, not one universal definition of 'optimal.' Severe triglyceride elevation is a different clinical problem and deserves prompt evaluation.
ApoB and Lp(a): useful, but not interchangeable
ApoB estimates the number of atherogenic particles. I reach for it when LDL-C may understate particle burden, especially with higher triglycerides, diabetes, insulin resistance, very low treated LDL-C, or an otherwise discordant risk picture.
Lp(a) is a largely inherited risk marker. It is not another version of LDL-C, and a high result usually changes how seriously I manage the risk factors we can modify.
Protocol
Risk-based shorthand for ApoB and Lp(a)
ApoB, general primary prevention when measured
- Level
- <90 mg/dL
- Clinical meaning
- A reasonable shorthand goal for many borderline or intermediate-risk adults.
ApoB, high risk
- Level
- <70 mg/dL
- Clinical meaning
- A risk-based goal when a lower atherogenic-particle burden is warranted.
ApoB, very high risk
- Level
- Roughly <55–60 mg/dL
- Clinical meaning
- A context-dependent shorthand aligned with intensive prevention. ApoB targets are treatment goals, not diagnostic normal ranges.
Lp(a), lower risk
- Level
- <75 nmol/L or <30 mg/dL
- Clinical meaning
- Lower inherited Lp(a)-related risk.
Lp(a), intermediate
- Level
- 75–124 nmol/L or 30–49 mg/dL
- Clinical meaning
- A gray zone that should be interpreted with the rest of the cardiovascular risk picture.
Lp(a), high
- Level
- ≥125 nmol/L or ≥50 mg/dL
- Clinical meaning
- A risk-enhancing result that favors earlier, more intensive management of modifiable risk.
| Marker and context | Level | Clinical meaning |
|---|---|---|
| ApoB, general primary prevention when measured | <90 mg/dL | A reasonable shorthand goal for many borderline or intermediate-risk adults. |
| ApoB, high risk | <70 mg/dL | A risk-based goal when a lower atherogenic-particle burden is warranted. |
| ApoB, very high risk | Roughly <55–60 mg/dL | A context-dependent shorthand aligned with intensive prevention. ApoB targets are treatment goals, not diagnostic normal ranges. |
| Lp(a), lower risk | <75 nmol/L or <30 mg/dL | Lower inherited Lp(a)-related risk. |
| Lp(a), intermediate | 75–124 nmol/L or 30–49 mg/dL | A gray zone that should be interpreted with the rest of the cardiovascular risk picture. |
| Lp(a), high | ≥125 nmol/L or ≥50 mg/dL | A risk-enhancing result that favors earlier, more intensive management of modifiable risk. |
Use the unit your laboratory reports. Do not convert Lp(a) between nmol/L and mg/dL with a fixed mathematical factor; particle size makes that conversion unreliable.
Glucose: know the diagnostic thresholds
A1C, fasting glucose, and a 2-hour oral glucose tolerance test look at related but different parts of glucose physiology. A person can cross a threshold on one test and not another.
Unless hyperglycemia is unequivocal, a diabetes diagnosis requires confirmation with a repeat abnormal result or a second abnormal test. Results near a cutoff deserve follow-up, not a label delivered by portal notification.
Protocol
ADA 2026 criteria for nonpregnant adults
A1C
- Below the prediabetes range
- <5.7%
- Prediabetes
- 5.7–6.4%
- Diabetes threshold
- ≥6.5%
Fasting plasma glucose
- Below the prediabetes range
- 70–99 mg/dL
- Prediabetes
- 100–125 mg/dL
- Diabetes threshold
- ≥126 mg/dL
2-hour 75-g OGTT
- Below the prediabetes range
- <140 mg/dL
- Prediabetes
- 140–199 mg/dL
- Diabetes threshold
- ≥200 mg/dL
| Test | Below the prediabetes range | Prediabetes | Diabetes threshold |
|---|---|---|---|
| A1C | <5.7% | 5.7–6.4% | ≥6.5% |
| Fasting plasma glucose | 70–99 mg/dL | 100–125 mg/dL | ≥126 mg/dL |
| 2-hour 75-g OGTT | <140 mg/dL | 140–199 mg/dL | ≥200 mg/dL |
A1C can be distorted by altered red blood cell turnover or assay interference, including iron or B12 deficiency, blood loss or transfusion, kidney disease, pregnancy, and some hemoglobin variants. When A1C and measured glucose do not agree, investigate the mismatch and use plasma glucose criteria when appropriate.
hsCRP: a risk signal, not a diagnosis
hsCRP can add cardiovascular risk information, but it does not tell you where inflammation comes from. I do not interpret it during an acute infection, just after an injury, or after unusually hard training.
Protocol
How to read hsCRP
<1 mg/L
- Risk shorthand
- Lower inflammatory cardiovascular risk
- What changes next
- Interpret with lipids, blood pressure, smoking, glycemia, kidney health, and known disease.
1–3 mg/L
- Risk shorthand
- Intermediate or average risk
- What changes next
- Use the full risk picture rather than treating hsCRP itself.
>3 mg/L
- Risk shorthand
- Higher risk if persistent
- What changes next
- Look for context and repeat when needed before calling it chronic low-grade inflammation.
≥2 mg/L
- Risk shorthand
- Risk-enhancing when persistent
- What changes next
- Can support a more intensive prevention discussion, especially when the lipid decision is uncertain.
>10 mg/L
- Risk shorthand
- Often an acute-phase signal
- What changes next
- Repeat after acute infection, injury, or another temporary cause has resolved.
| Level | Risk shorthand | What changes next |
|---|---|---|
| <1 mg/L | Lower inflammatory cardiovascular risk | Interpret with lipids, blood pressure, smoking, glycemia, kidney health, and known disease. |
| 1–3 mg/L | Intermediate or average risk | Use the full risk picture rather than treating hsCRP itself. |
| >3 mg/L | Higher risk if persistent | Look for context and repeat when needed before calling it chronic low-grade inflammation. |
| ≥2 mg/L | Risk-enhancing when persistent | Can support a more intensive prevention discussion, especially when the lipid decision is uncertain. |
| >10 mg/L | Often an acute-phase signal | Repeat after acute infection, injury, or another temporary cause has resolved. |
The categories overlap: 2–3 mg/L sits in the traditional intermediate band and also meets the ≥2 mg/L risk-enhancing threshold. The result earns attention when it is measured in a stable state, persists, and changes cardiovascular management.
Kidney function needs both filtration and urine context
An eGFR of 60 or higher is often reassuring, but it is not enough to rule out kidney disease in someone at risk. Urine albumin can rise before filtration falls, which is why eGFR and urine albumin-to-creatinine ratio, or uACR, answer different questions.
Protocol
eGFR and uACR
eGFR
- Category
- ≥60 mL/min/1.73 m²
- How I interpret it
- Often reassuring, but not sufficient by itself in people with diabetes, hypertension, cardiovascular disease, prior kidney injury, or other kidney risk.
uACR
- Category
- <30 mg/g
- How I interpret it
- The KDIGO normal-to-mildly increased category. It does not cancel an abnormal eGFR or other evidence of kidney disease.
uACR
- Category
- 30–299 mg/g
- How I interpret it
- Moderately increased albuminuria. Confirm persistence and address blood pressure, glycemia, medications, and cardiovascular risk.
uACR
- Category
- ≥300 mg/g
- How I interpret it
- Severely increased albuminuria and a higher-risk finding that warrants timely clinical follow-up.
| Marker | Category | How I interpret it |
|---|---|---|
| eGFR | ≥60 mL/min/1.73 m² | Often reassuring, but not sufficient by itself in people with diabetes, hypertension, cardiovascular disease, prior kidney injury, or other kidney risk. |
| uACR | <30 mg/g | The KDIGO normal-to-mildly increased category. It does not cancel an abnormal eGFR or other evidence of kidney disease. |
| uACR | 30–299 mg/g | Moderately increased albuminuria. Confirm persistence and address blood pressure, glycemia, medications, and cardiovascular risk. |
| uACR | ≥300 mg/g | Severely increased albuminuria and a higher-risk finding that warrants timely clinical follow-up. |
Do not diagnose chronic kidney disease from one incidental result. Repeat an unexpected abnormality under stable conditions and interpret it with the urine sample, trend, medications, and clinical history.
Context can change the number
Some of the most over-optimized biomarkers are also the most context-dependent. This is where I slow down and ask what could move the assay, what symptoms fit, and whether treating the number improves anything that matters.
Protocol
Iron, B12, vitamin D, thyroid, and reproductive hormones
Ferritin
- Practical interpretation
- <30 ng/mL supports depleted iron stores in the right context. Inflammation can raise ferritin and hide deficiency, so CBC, transferrin saturation, symptoms, and the reason for iron loss matter.
- What I would not do
- I would not prescribe a universal ferritin target of 100 ng/mL.
Vitamin B12
- Practical interpretation
- <200–250 pg/mL is generally low. If B12 is 150–399 pg/mL and symptoms or risk raise concern, check methylmalonic acid, or MMA, while accounting for kidney function.
- What I would not do
- I would not chase a high B12 level after deficiency is corrected.
25-hydroxyvitamin D
- Practical interpretation
- There is no validated universal optimal target for disease prevention in healthy adults. Test for a reason, such as a bone, calcium, absorption, or treated-deficiency question.
- What I would not do
- I would not use routine serial testing to tune every healthy adult to the same number.
TSH
- Practical interpretation
- Use the laboratory and assay-specific range, roughly 0.4–4.0 mIU/L for many adults. Age, medications, and life stage can change interpretation.
- What I would not do
- I would not mandate a TSH of 1–2 mIU/L for everyone.
Estradiol and FSH
- Practical interpretation
- There is no single optimal range during the menopausal transition. Levels fluctuate and should answer a specific diagnostic question.
- What I would not do
- I would not use one generic hormone panel to diagnose symptoms or titrate routine treatment.
| Marker | Practical interpretation | What I would not do |
|---|---|---|
| Ferritin | <30 ng/mL supports depleted iron stores in the right context. Inflammation can raise ferritin and hide deficiency, so CBC, transferrin saturation, symptoms, and the reason for iron loss matter. | I would not prescribe a universal ferritin target of 100 ng/mL. |
| Vitamin B12 | <200–250 pg/mL is generally low. If B12 is 150–399 pg/mL and symptoms or risk raise concern, check methylmalonic acid, or MMA, while accounting for kidney function. | I would not chase a high B12 level after deficiency is corrected. |
| 25-hydroxyvitamin D | There is no validated universal optimal target for disease prevention in healthy adults. Test for a reason, such as a bone, calcium, absorption, or treated-deficiency question. | I would not use routine serial testing to tune every healthy adult to the same number. |
| TSH | Use the laboratory and assay-specific range, roughly 0.4–4.0 mIU/L for many adults. Age, medications, and life stage can change interpretation. | I would not mandate a TSH of 1–2 mIU/L for everyone. |
| Estradiol and FSH | There is no single optimal range during the menopausal transition. Levels fluctuate and should answer a specific diagnostic question. | I would not use one generic hormone panel to diagnose symptoms or titrate routine treatment. |
Low or borderline values should be interpreted with symptoms, diet, absorption, medications, organ function, and prior results. Treat a deficiency or disease, not a wellness leaderboard.
AgeTSH, kidney estimates, and nutrient markers can shift with age, and treatment benefit depends on baseline risk.
Medications and supplementssteroids can raise glucose; biotin can interfere with some thyroid assays; acid suppression, metformin, diuretics, and many other drugs can change what should be measured.
Kidney functionreduced filtration can raise MMA and changes how several biomarkers and medications should be interpreted.
Ancestry and hemoglobin variantssome variants can distort A1C depending on the assay. Ancestry can raise the chance of a variant, but it should prompt the right question, not an assumption.
Training and illnesshard exercise, dehydration, infection, injury, and poor recovery can temporarily move inflammatory, liver, kidney, glucose, and muscle markers.
Menstruation and pregnancy historybleeding patterns can change iron stores; prior gestational diabetes or preeclampsia changes future cardiometabolic risk; current pregnancy uses different glucose and thyroid criteria.
Perimenopause and menopausethere is no single optimal estradiol or FSH range. In adults over 45 with a typical symptom and cycle history, that history usually leads. Test when symptoms begin younger, the pattern is atypical, or a competing diagnosis needs to be ruled out.
What changes next
A useful interpretation ends with a decision. The next move may be no action, a repeat, a second test, a risk calculation, a treatment change, or prompt evaluation. It should not automatically be a supplement and another panel.
Protocol
From result to action
One mild result outside the reference range
- Next step
- Check preparation, recent illness or training, medications, and prior values; repeat if the result could be transient.
- Why
- A flag is not the same as a diagnosis.
A diagnostic threshold is crossed
- Next step
- Confirm as the relevant guideline requires and assess symptoms and competing explanations.
- Why
- The diagnostic label changes follow-up and treatment.
A risk threshold is crossed
- Next step
- Recalculate the full risk picture and discuss whether prevention intensity should change.
- Why
- Risk markers matter through the decisions they alter.
A personal treatment target is not reached
- Next step
- Check adherence, response, side effects, secondary causes, and whether the target still fits before intensifying.
- Why
- Targets are chosen for a reason and should be revisited with the same logic.
The result is extreme or comes with concerning symptoms
- Next step
- Contact a clinician promptly or seek urgent care based on the symptom and result.
- Why
- Routine optimization rules no longer apply.
| Pattern | Next step | Why |
|---|---|---|
| One mild result outside the reference range | Check preparation, recent illness or training, medications, and prior values; repeat if the result could be transient. | A flag is not the same as a diagnosis. |
| A diagnostic threshold is crossed | Confirm as the relevant guideline requires and assess symptoms and competing explanations. | The diagnostic label changes follow-up and treatment. |
| A risk threshold is crossed | Recalculate the full risk picture and discuss whether prevention intensity should change. | Risk markers matter through the decisions they alter. |
| A personal treatment target is not reached | Check adherence, response, side effects, secondary causes, and whether the target still fits before intensifying. | Targets are chosen for a reason and should be revisited with the same logic. |
| The result is extreme or comes with concerning symptoms | Contact a clinician promptly or seek urgent care based on the symptom and result. | Routine optimization rules no longer apply. |
Repeat the marker you are trying to change on a timeline that matches the intervention. Do not keep expanding the panel unless a new question appears.
Clinical lens
How I’d decide
Use this section as a second pass after the main answer, not as homework before you know what the page is saying.
Who it’s for
Adults trying to understand common prevention labs, decide which results deserve a repeat or workup, and have a more useful conversation about cardiovascular, metabolic, kidney, thyroid, or nutrient risk.
Who should skip it
Do not use a general guide to manage a severe result or new symptoms on your own. Very high glucose or triglycerides, major electrolyte abnormalities, rapidly worsening kidney function, severe anemia, chest pain, fainting, or neurologic symptoms need timely clinical care.
Measure before / after
Start with the smallest panel that answers the question: a standard lipid panel, A1C or fasting glucose, CBC, CMP, creatinine/eGFR, and blood pressure. Add Lp(a), ApoB, uACR, hsCRP, thyroid, iron, B12, vitamin D, or other tests only when risk, symptoms, medications, or prior results make them actionable.
What I’d do first
I would classify the number before trying to improve it. Confirm a possible diagnosis, calculate risk before choosing a lipid target, repeat results that may be transient, and follow the marker that is tied to the treatment decision.
What would change my mind
Persistence, symptoms, family history, known disease, medication exposure, and a result that crosses a diagnostic or treatment threshold all raise the stakes. A single mild flag without a coherent story often lowers them.
Frequently Asked Questions
Is the reference range the same as a healthy or optimal range?
No. A reference range describes how a laboratory reports results, often from a comparison population and a specific assay. Diagnostic thresholds classify disease or risk. Treatment targets are chosen from your risk and clinical context. They may overlap, but they are not interchangeable.
What should I do with one result just outside the range?
Check whether you were ill, dehydrated, fasting, training hard, or taking a medication or supplement that affects the test. Compare prior values and repeat when the result could be transient. Act faster when the abnormality is severe, fits symptoms, or crosses a validated diagnostic threshold.
Should everyone get ApoB?
Not necessarily. ApoB is most useful when it could change cardiovascular risk assessment or treatment. I prioritize it when triglycerides are elevated, diabetes or insulin resistance is present, LDL-C is already low on treatment, or LDL-C seems discordant with the rest of the risk picture.
How often should Lp(a) be checked?
Usually once in adulthood because genetics drive most of the level. Repeat testing can make sense in selected clinical situations or as Lp(a)-directed treatments evolve, but routine frequent checks rarely add useful information.
How often should I repeat prevention labs?
Repeat on the timeline of the decision. A medication change may call for weeks-to-months follow-up, a treated deficiency should be checked after enough time to respond, and stable prevention markers often need much less frequent testing. Monthly broad panels usually add noise, not control.
References & citations
- 1.2026 ACC/AHA Guideline on the Management of Dyslipidemia. PMID 41824590; DOI 10.1161/CIR.0000000000001423
- 2.American Diabetes Association. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2026
- 3.National Lipid Association focused update on lipoprotein(a), 2024. PMID 38565461
- 4.National Lipid Association Expert Clinical Consensus on ApoB, 2024. PMID 39256087
- 5.Inflammation and Cardiovascular Disease: 2025 ACC Scientific Statement. PMID 41020749; DOI 10.1016/j.jacc.2025.08.047
- 6.KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease
- 7.Recommendations for diagnosis, treatment, and prevention of iron deficiency and iron deficiency anemia. HemaSphere, 2024
- 8.NIH Office of Dietary Supplements: Vitamin B12 Fact Sheet for Health Professionals
- 9.Endocrine Society Vitamin D for the Prevention of Disease guideline, 2024. PMID 38828931
- 10.American Thyroid Association-commissioned review of TSH and thyroid hormone testing. PMID 37655789
- 11.ACOG 2025 guidance on hormone testing during the menopausal transition
Related Guides
Next step
Turn the guide into the right next decision.
If this page raised a real clinical question, start with the practice details. If you are still learning, get the weekly letter. If you are comparing tests, use the testing hub before buying another panel.